Global Filgrastim Biosimilars Market Report 2024

Filgrastim Biosimilars Global Market Report 2024 – By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing organization), By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Filgrastim Biosimilar Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Filgrastim Biosimilars Market Definition And Segments

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

The two main types of manufacturing for the filgrastim biosimilar market are in-house manufacturing and contract manufacturing organization. A contract manufacturing organization, also known as a contract development and manufacturing organization, is a corporation that provides entire services to other pharma firms on a contractual basis, from drug discovery to drug production. The different applications include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure.

The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to aging population, increase in healthcare access. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies.

Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market

The increasing prevalence of neutropenia is expected to propel the growth of the filgrastim biosimilar market going forward. Neutropenia refers to a condition where the body does not have enough neutrophils, which are an important type of white blood cell that fights infections. Filgrastim biosimilars work by stimulating the production of neutrophils in the bone marrow, which increases the neutrophil count and helps fight infections. For instance, in August 2022, according to the National Center for Biotechnology Information, a US-based database for biomedical literature, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Thus, the increasing prevalence of neutropenia is driving the growth of the filgrastim biosimilar market.

Government-Led Biosimilar Initiatives Fuel Growth In The Filgrastim Biosimilar Market

Government initiatives for the development of biosimilars are expected to drive the filgrastim biosimilar markets market over the coming years. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government's initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the filgrastim biosimilar markets market.

Major companies operating in the filgrastim biosimilars market report are Teva Pharmaceutical Industries Ltd., Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd., Abbott Laboratories, Reliance Life Science Pvt. Ltd., Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd., Apotex Pty Ltd., Mylan, Kyowa Kirin Co. Ltd., Lupin Limited, Biocon Biologics, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Mochida Pharmaceutical, Fuji Pharma, Amgen (Europe) GmbH, Napp Pharmaceuticals, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

Challenges And Hurdles In The Filgrastim Biosimilar Market: Navigating Regulatory Complexities And Patent Disputes

Stringent regulations imposed on approvals of biosimilars are anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration require double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. Sandoz, for example, received FDA approval for its first biosimilar, Zarxio (filgrastim-and) of the original biologic Neupogen. The consent depended on a comprehensive package of analytical, nonclinical, and clinical information that verified that Zarxio is highly similar to the US-licensed reference product. To get this approval, Sandoz even had to fight a legal battle with Amgen, which claims that Sandoz has infringed on its manufacturing process. These kinds of hurdles can restrict the growth of the filgrastim biosimilar market.

Amneal Pharmaceuticals' Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant DNA Technology

Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States indicated for the treatment and prevention of febrile neutropenia. It promotes the expansion and specialization of neutrophils originating from dedicated precursor cells, triggers their maturation, and improves the viability and efficiency of fully developed neutrophils, leading to dosage-dependent rises in neutrophil counts. The launch of Fylnetra contributes to the next wave of affordable medicines and drives access across patients, providers, and payors.

Amneal Pharmaceuticals And Kashiv Biosciences Revolutionize Cancer Care With Releuko (Filgrastim-Ayow), A Breakthrough Biosimilar For Febrile Neutropenia

Major companies operating in the filgrastim biosimilar market are developing innovative products such as Releuko (filgrastim-ayow) to better serve patients. Releuko (filgrastim-ayow) is a biosimilar referencing Neupogen (filgrastim) and is indicated for the treatment and prevention of febrile neutropenia in patients with cancer undergoing chemotherapy. For instance, in November 2022, Amneal Pharmaceuticals, a US-based pharmaceutical company, and Kashiv Biosciences, a US-based biosciences company launched Releuko (filgrastim-ayow) in the US market. It is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or peg filgrastim products. The approval of Releuko marks the first biosimilar for Amneal, with two more decisions expected by the end of the year.

Biocon Biologics' Transformative Acquisition Of Viatris Inc.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc. for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc. is a US-based pharmaceutical company that has developed a biosimilar of peg filgrastim.

North America was the largest region in the filgrastim biosimilar markets market in 2023. The Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The filgrastim biosimilar markets market research report is one of a series of new reports from The Business Research Company that provides filgrastim biosimilar markets market statistics, including filgrastim biosimilar markets industry global market size, regional shares, competitors with a filgrastim biosimilar markets market share, detailed filgrastim biosimilar markets market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilar markets industry. This filgrastim biosimilar markets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Filgrastim Biosimilars Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $1.1 billion
Revenue Forecast In 2033 $1.66 billion
Growth Rate CAGR of 10.7% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Teva Pharmaceutical Industries Ltd; Novartis International AG; Biocon Limited; Intas Biopharmaceuticals; Dr. Reddy's Laboratories; Pfizer; Cadila Healthcare Ltd; Abbott Laboratories; Reliance Life Science Pvt. Ltd; Gennova Biopharmaceuticals (Emcure); Sandoz Pty Ltd; Apotex Pty Ltd; Mylan; Kyowa Kirin Co. Ltd; Lupin Limited; Biocon Biologics; Coherus Biosciences Inc.; North China Pharmaceutical Corporation; Tonghua Dongbaoare; Beijing SL Pharmaceutical; Mochida Pharmaceutical; Fuji Pharma; Amgen (Europe) GmbH; Napp Pharmaceuticals; Adello Biologics; Apobiologix (Apotex); Hospira; Tanvex BioPharma; Eurofarma Laboratórios
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Filgrastim Biosimilars Market Characteristics

    3. Filgrastim Biosimilars Market Trends And Strategies

    4. Filgrastim Biosimilars Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Filgrastim Biosimilars Market Size and Growth

    5.1. Global Filgrastim Biosimilars Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Filgrastim Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Filgrastim Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Filgrastim Biosimilars Market Segmentation

    6.1. Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    In-House Manufacturing

    Contract Manufacturing Organization

    6.2. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oncology

    Chronic And Autoimmune Diseases

    Blood Disorders

    Growth Hormone Deficiency

    Infectious Diseases

    Other Applications

    6.3. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    7. Filgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Filgrastim Biosimilars Market

    8.1. Asia-Pacific Filgrastim Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Filgrastim Biosimilars Market

    9.1. China Filgrastim Biosimilars Market Overview

    9.2. China Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Filgrastim Biosimilars Market

    10.1. India Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Filgrastim Biosimilars Market

    11.1. Japan Filgrastim Biosimilars Market Overview

    11.2. Japan Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Filgrastim Biosimilars Market

    12.1. Australia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Filgrastim Biosimilars Market

    13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Filgrastim Biosimilars Market

    14.1. South Korea Filgrastim Biosimilars Market Overview

    14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Filgrastim Biosimilars Market

    15.1. Western Europe Filgrastim Biosimilars Market Overview

    15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Filgrastim Biosimilars Market

    16.1. UK Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Filgrastim Biosimilars Market

    17.1. Germany Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Filgrastim Biosimilars Market

    18.1. France Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Filgrastim Biosimilars Market

    19.1. Italy Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Filgrastim Biosimilars Market

    20.1. Spain Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Filgrastim Biosimilars Market

    21.1. Eastern Europe Filgrastim Biosimilars Market Overview

    21.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Filgrastim Biosimilars Market

    22.1. Russia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Filgrastim Biosimilars Market

    23.1. North America Filgrastim Biosimilars Market Overview

    23.2. North America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Filgrastim Biosimilars Market

    24.1. USA Filgrastim Biosimilars Market Overview

    24.2. USA Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Filgrastim Biosimilars Market

    25.1. Canada Filgrastim Biosimilars Market Overview

    25.2. Canada Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Filgrastim Biosimilars Market

    26.1. South America Filgrastim Biosimilars Market Overview

    26.2. South America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Filgrastim Biosimilars Market

    27.1. Brazil Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Filgrastim Biosimilars Market

    28.1. Middle East Filgrastim Biosimilars Market Overview

    28.2. Middle East Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Filgrastim Biosimilars Market

    29.1. Africa Filgrastim Biosimilars Market Overview

    29.2. Africa Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

    30.1. Filgrastim Biosimilars Market Competitive Landscape

    30.2. Filgrastim Biosimilars Market Company Profiles

    30.2.1. Teva Pharmaceutical Industries Ltd

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Novartis International AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Biocon Limited

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Intas Biopharmaceuticals

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Dr. Reddy's Laboratories

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Filgrastim Biosimilars Market Other Major And Innovative Companies

    31.1. Pfizer

    31.2. Cadila Healthcare Ltd

    31.3. Abbott Laboratories

    31.4. Reliance Life Science Pvt. Ltd

    31.5. Gennova Biopharmaceuticals (Emcure)

    31.6. Sandoz Pty Ltd

    31.7. Apotex Pty Ltd

    31.8. Mylan

    31.9. Kyowa Kirin Co. Ltd

    31.10. Lupin Limited

    31.11. Biocon Biologics

    31.12. Coherus Biosciences Inc.

    31.13. North China Pharmaceutical Corporation

    31.14. Tonghua Dongbaoare

    31.15. Beijing SL Pharmaceutical

    32. Global Filgrastim Biosimilars Market Competitive Benchmarking

    33. Global Filgrastim Biosimilars Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

    35. Filgrastim Biosimilars Market Future Outlook and Potential Analysis

    35.1 Filgrastim Biosimilars Market In 2028 - Countries Offering Most New Opportunities

    35.2 Filgrastim Biosimilars Market In 2028 - Segments Offering Most New Opportunities

    35.3 Filgrastim Biosimilars Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Teva Pharmaceutical Industries Ltd Financial Performance
  • Table 75: Novartis International AG Financial Performance
  • Table 76: Biocon Limited Financial Performance
  • Table 77: Intas Biopharmaceuticals Financial Performance
  • Table 78: Dr. Reddy's Laboratories Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Teva Pharmaceutical Industries Ltd Financial Performance
  • Figure 75: Novartis International AG Financial Performance
  • Figure 76: Biocon Limited Financial Performance
  • Figure 77: Intas Biopharmaceuticals Financial Performance
  • Figure 78: Dr. Reddy's Laboratories Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Neutropenia Biologic Drug Treatment Global Market Report 2024 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 – By Type (Pegfilgrastim, Lenograstim, Filgrastim, Other Types), By Product (Tablet, Capsule, Other Products), By Application (Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pegfilgrastim Biosimilars Global Market Report 2024 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Trastuzumab Biosimilars Global Market Report 2024 – By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Rituximab Biosimilars Global Market Report 2024 – By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), By Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Mail Order) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report

Frequently Asked Questions

What is the definition of the filgrastim biosimilars market?

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections. For further insights on the filgrastim biosimilars market, request a sample here

How will the filgrastim biosimilars market drivers and restraints affect the filgrastim biosimilars market dynamics? What forces will shape the filgrastim biosimilars industry going forward?

The filgrastim biosimilars market growth is aided by government initiatives for the development of biosimilars. However, some filgrastim biosimilars market restraints include stringent regulations imposed on approvals of biosimilars. For further insights on the filgrastim biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the filgrastim biosimilars market?

The filgrastim biosimilars market is expected to reach $1.33 billion in 2027 at a rate of 8.9%. For further insights on the filgrastim biosimilars market, request a sample here

How is the filgrastim biosimilars market segmented?

The global filgrastim biosimilars market is segmented as
1) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Applications
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing Oraganization
For further insights on the filgrastim biosimilars market, request a sample here

Which region has the largest share of the filgrastim biosimilars market? What are the largest region's market size and growth rate?

North America was the largest region in the filgrastim biosimilars market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the filgrastim biosimilars market?

Key competitors in the filgrastim biosimilars market are, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, Aryogen Biopharma, Claris Life Sciences, Adello Biologics, Hospira (Pfizer), Gennova Biopharmaceuticals, Teva Pharmaceuticals Industries, F. Hoffmann-La Roche Ltd., Lupin Limited, Abbott Laboratories Inc., Reliance Life Sciences Pvt. Ltd., Novartis AG. For further insights on the filgrastim biosimilars market, request a sample here.

What are the key trends in the filgrastim biosimilars market?

Major trends influencing the filgrastim biosimilars market include increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For further insights on the filgrastim biosimilars market, request a sample here.

What are the major opportunities in the filgrastim biosimilars market? What are the strategies for the filgrastim biosimilars market?

For detailed insights on the major opportunities and strategies in the filgrastim biosimilars market, request a sample here.

How does the filgrastim biosimilars market relate to the overall economy and other similar markets?

For detailed insights on filgrastim biosimilars market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the filgrastim biosimilars industry?

For detailed insights on the mergers and acquisitions in the filgrastim biosimilars industry, request a sample here.

What are the key dynamics influencing the filgrastim biosimilars market growth? SWOT analysis of the filgrastim biosimilars market.

For detailed insights on the key dynamics influencing the filgrastim biosimilars market growth and SWOT analysis of the filgrastim biosimilars industry, request a sample here.